Improving Outcomes and Resource Use in Multiple Sclerosis: What are the Benefits Associated With an Early Treatment Strategy With Fingolimod?

• Главные авторы: João Carrasco (Автор), Daniel Viriato (Автор), Joaquim Fonseca (Автор), João Miguel Fernandes (Автор), João José Cerqueira (Автор)
• Формат: ‌
• Опубликовано: Formifarma, LDA., 2016-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective: This analysis aims to estimate the cost-effectiveness of early treatment versus delayed treatment with fingolimod 0.5 mg/day in patients with relapsing-remitting multiple sclerosis. Study Type: Economic evaluation of health technologies Local: Portugal Population: Multiple sclerosis patie...